Johnson & Johnson (JNJ) news

Older JNJ news events, each with the realized, point-in-time move the market made — page 9 of 10. Back to the JNJ overview → · Full JNJ reaction history →

Latest news

Recent JNJ events, each with its measured reaction. (Page 9 of 10.)

DateHeadlineEventSource5-minTo close
Johnson & Johnson Completes Acquisition of Proteologix, Inc.Press releaseBusiness Wire+0.04%+0.58%
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's diseasePress releasePR Newswire+0.04%+0.58%
More than 60 Law Firms Oppose J&J Prepack Bankruptcy SchemePress releaseBusiness Wire-0.13%+0.18%
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous inductionPress releasePR Newswire+0.23%+1.83%
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc ProductsPress releaseBusiness Wire+0.04%-0.10%
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancerPress releasePR Newswire+0.78%+0.64%
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 studyPress releasePR Newswire+0.78%+0.64%
TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myelomaPress releasePR Newswire+0.34%+0.28%
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy StrategyPress releaseBusiness Wire+0.04%-0.01%
DePuy Synthes Receives 510(k) FDA Clearance of the VELYS™ Robotic-Assisted Solution for Use in Unicompartmental Knee Arthroplasty ProceduresPress releasePR Newswire-0.07%+0.27%
Johnson & Johnson to Host Investor Conference Call on Second-Quarter ResultsPress releaseBusiness Wire-0.39%-1.36%
Johnson & Johnson Completes Acquisition of Shockwave MedicalPress releaseBusiness Wire+0.26%+0.76%
Form SD JOHNSON & JOHNSONSEC filing · Form SDSEC EDGAR+0.89%+0.40%
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic DermatitisPress releaseBusiness Wire-0.72%-1.64%
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic DermatitisPress releaseGlobeNewswire-0.72%-1.64%
Form CERT JOHNSON & JOHNSONSEC filing · Form CERTSEC EDGAR-0.13%-0.17%
Form 8-A12B JOHNSON & JOHNSONSEC filing · Form 8-A12BSEC EDGAR-0.01%-0.36%
Form 8-K JOHNSON & JOHNSON For: May 20SEC filing · Form 8-KSEC EDGAR-0.01%-0.36%
Biosense Webster Presents Late-Breaking Data from admIRE Clinical Trial at the Heart Rhythm Society Annual MeetingPress releasePR Newswire-0.57%-1.20%
Form 8-K JOHNSON & JOHNSON For: May 17SEC filing · Form 8-KSEC EDGAR-0.12%+0.27%
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis TreatmentPress releaseBusiness Wire-0.31%+0.84%
Form 13F-HR JOHNSON & JOHNSON For: Mar 31SEC filing · Form 13F-HRSEC EDGAR-0.19%+0.79%
Biosense Webster Launches New Version of CARTO™ 3 Electro-Anatomical Mapping SystemPress releasePR Newswire+0.16%-0.11%
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferencePress releaseBusiness Wire+0.03%+0.58%
Form 10-Q JOHNSON & JOHNSON For: Mar 31SEC filing · Form 10-QSEC EDGAR-0.62%+1.62%
Form 8-K JOHNSON & JOHNSON For: May 01SEC filing · Form 8-KSEC EDGAR-0.62%+1.62%
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” ReorganizationPress releaseBusiness Wire-0.62%+1.62%
Form 8-K JOHNSON & JOHNSON For: Apr 25SEC filing · Form 8-KSEC EDGAR-0.59%-1.56%
Prevent Blindness Declares May as First-ever Inherited Retinal Disease (IRD) Genetic Testing Awareness MonthPress releasePR Web-0.24%+0.59%
Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)Press releaseBusiness Wire-0.27%-0.03%
Illinois Jury Awards $45 Million in Mesothelioma Case Against Johnson & Johnson, Kenvue, Inc.Press releaseBusiness Wire-0.27%+0.41%
Form 8-K JOHNSON & JOHNSON For: Apr 16SEC filing · Form 8-KSEC EDGAR+1.19%+0.31%
Form 8-K/A JOHNSON & JOHNSON For: Apr 16SEC filing · Form 8-KSEC EDGAR-0.11%-0.25%
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%Press releaseBusiness Wire+1.19%+0.31%
Johnson & Johnson Reports Q1 2024 ResultsPress releaseBusiness Wire+1.19%+0.31%
Signature Resolution Welcomes Hon. Eddie C. Sturgeon (Ret.) to Panel of NeutralsPress releasePR Web-0.13%-0.65%
Engel & Völkers Continues Franchise Expansion in Florida with New Location in TrinityPress releasePR Web+0.14%-0.26%
Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare ConferencePress releaseBusiness Wire-0.13%+0.49%
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of TherapyPress releasePR Newswire+0.14%-0.26%
Johnson & Johnson to Acquire Shockwave MedicalPress releaseBusiness Wire+0.14%+0.24%
Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment CorporationPress releaseBusiness Wire+0.14%+0.24%
Companies are paying $500 per hour to people who participate in focus groupsPress releasePR Web-0.03%+0.59%
Johnson & Johnson to Participate in the BofA Securities Health Care ConferencePress releaseBusiness Wire-0.26%-2.24%
Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE™ Platform for the Treatment of Paroxysmal Atrial FibrillationPress releasePR Newswire-0.01%-0.12%
The Next Great Biotech Boom Has ArrivedPress releasePR Newswire-0.43%-0.29%
Form ARS JOHNSON & JOHNSON For: Dec 31SEC filing · Form ARSSEC EDGAR-1.19%-0.88%
Form DEF 14A JOHNSON & JOHNSON For: Apr 25SEC filing · Form DEFSEC EDGAR-1.19%-0.88%
Form DEFA14A JOHNSON & JOHNSONSEC filing · Form DEFA14ASEC EDGAR-1.19%-0.88%
Johnson & Johnson to Host Investor Conference Call on First-Quarter ResultsPress releaseBusiness Wire+0.55%+1.00%
Johnson & Johnson Completes Acquisition of AmbrxPress releaseBusiness Wire-0.03%-0.71%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground